Purpose Imatinib mesylate (Imatinib), clinically employed for chronic myeloid leukemia and gastrointestinal stromal tumors, is a selective inhibitor of the tyrosine kinases, c-abl, c-kit and PDGFRs. Due to the frequent expression of these genes in breast cancer cells, the clinical eYcacy of Imatinib has recently been investigated in patients with advanced and metastatic breast cancer. Here, we have studied the eVects of Imatinib on human MA-11 breast carcinoma cells, expressing both c-abl and PDGFRbeta, in vitro and in mouse xenografts. Methods The eVects of Imatinib mesylate on the human MA-11 breast carcinoma cell line were studied in vitro and in xenografts. Results Daily intraperitoneal treatment with 60 mg/kg Imatinib for 9 days of athymic nude mice pre-implanted subcutaneously with MA-11 cells did not result in an antitumor eVect, but rather increased the take rate of 3 £ 10 4 cells from 30.8 to 84.6% and caused the appearance of large abdominal masses in 30% of mice. To investigate the mechanism(s) of the observed eVects of Imatinib on MA-11 tumors, we exposed the cells in vitro to Imatinib for 9 days. The surviving population, expanded in culture, showed increased motility and over-expressed a set of genes associated with aggressive behavior. Also, several genes belonging to the Wnt and the MAPK pathway were diVerentially expressed. In promoter activation assays, Imatinib increased the promoter activity driven by both Wnt and MAPK/ERK-1/2. Conclusions Our data suggest caution in the clinical use of Imatinib in breast cancer patients; the comparison of Imatinib-surviving breast cancer cells with parental cells may help deWne the regulatory pathways involved in the increased malignancy of residual tumor cells that survive therapy, ultimately providing important therapeutic targets.
Introduction
Every year, more than 1 million women are newly diagnosed with breast cancer worldwide [1] . One of the most exciting areas of improvement in the treatment of breast cancer is the development of novel targeted and biological therapeutic agents, such as Imatinib mesylate (Imatinib), a 2-phenylaminopyrimidine derivative that speciWcally inhibits the tyrosine kinase enzymes, c-Abl, PDGFR, and c-Kit [2, 3] . Imatinib was Wrst developed to speciWcally inhibit Bcr-Abl, a fusion protein with kinase activity present in chronic myeloid leukemia (CML) patients. It has been widely used for treatment of patients with CML and gastrointestinal stromal tumors and is under investigation in several malignancies, including breast cancer [4, 5] . Also, potentiation of chemotherapy by Imatinib in breast carcinoma cell lines has recently been reported [6] .
Recent evidence suggests that breast cancer originates from and is maintained by a sub-population of stem cell-like cells, named cancer-initiating cells or cancer stem cells (CSC), able to diVerentiate along diVerent pathways.
The identiWcation and characterization of breast CSC has important diagnostic, prognostic and therapeutic implications [4] [5] [6] [7] . Originally, breast CSC were described as CD44 + CD24 ¡/low cells. In the present study, we have employed as breast cancer model the human MA-11 breast carcinoma cell line, established from bone marrow micrometastases of a breast cancer patient. We have previously reported [7] that in MA-11 cells CD24 expression ranges from 0 to 1,120,000 molecules/cell, with an average number of 214,000 molecules/ cell. All cells in the MA-11 line express CD44, ranging from 900,000 to 8,800,000/cell, with an average number of 4,100,000 molecules/cell. Therefore, the MA-11 line is composed of both CD44 + CD24 ¡/low and CD44 + CD24 high sub-populations. Upon in vitro culture as mammospheres under stem cell-like conditions, MA-11 cells acquire increased tumorigenicity and display reduced levels of CD24 compared with parental adherent cells [22] . However, the level of CD24 expression is neither a stable feature of mammosphere-forming cells nor confers tumorigenic potential to MA-11 cells; in fact, upon passage of MA-11 mammospheres into serum-supplemented cultures, CD24 expression is restored; the rapid increase in CD24 expression is consistent with up-regulation of the antigen, and not with in vitro selection of CD24 + cells [7] . Also, the tumorigenicity of sorted CD44 + CD24
¡ and CD44 + CD24
high MA-11 cells is equal. Single cell-sorted CD24 ¡ and CD24 high MA-11 give rise in vitro to cell populations with heterogeneous CD24 expression; subcutaneous tumors derived from sorted CD24 ¡ sub-populations and single-cell clones have levels of CD24 expression similar to the unsorted cells, suggesting that the level of expression of CD24 is associated with but does not contribute to tumorigenicity [7] . We have also previously reported [7] that CSC-enriched MA-11 mammospheres have activated speciWc signal transduction pathways, including MAPK and Wnt.
Here, we have studied the eVects of Imatinib on MA-11 cells in vitro and in vivo and report that treatment with Imatinib results in increased tumorigenicity and malignancy of MA-11 cells.
Materials and methods

Cell culture
MA-11 cells were cultured in RPMI-1640 (Mediatech Inc. Herndon, VA) additioned with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) at 37°C in a 5% CO 2 humidiWed incubator. Cells were used between passages 10 and 20 and tested routinely for mycoplasma contamination.
Tumor implantation
Animal studies were done under a protocol approved by the Institutional Animal Care and Use Committee. For s.c. injection, cells were resuspended in 100 l PBS and injected subcutaneously into the right Xank of the animals.
Wound healing assay
To perform the wound healing assay, a wound in a conXuent MA-11 cell monolayer was introduced using a pipette tip. The monolayers were observed over a time course of 3-24 h.
Flow cytometric analysis
Mouse anti-human CD24 (clone ML5) and anti-human CD44 (clone G44-26) monoclonal antibodies were from BD Biosciences (San Jose, CA). Cell surface CD24 expression was quantitated using the quantum simply cellular system (Bangs Laboratories, Fishers, IN), as previously described [8] . And 5 £ 10 5 cells/sample were incubated with saturating concentrations (10 g/ml) of antibodies for 30 min at 4°C. Standard curves of beads with Wxed antibody-binding capacity and samples were analyzed on a FACSVantage Xow cytometer (BD Biosciences, San Jose, CA). Antibody-binding capacity for each cell population was calculated using the QuickCal v.2.3. software (Bangs Laboratories), employing median histogram values and linear regression analyses.
Microarray analysis
Total RNA was isolated from Imatinib-and mock-treated MA-11 cells using trizol phenol-based extraction. The quality of the RNA was assessed by gel electrophoresis and A 260 /A 280 ratio. Microarray analyses were performed by Ocean Ridge Biosciences (ORB, Palm Beach Gardens, FL) using human exonic evidence-based oligonucleotide (HEEBO) microarrays (http://alizadehlab.stanford.edu/) containing approximately 50,000 70-mer probes complementary to constitutive exons of most human genes, as well as alternatively spliced exons, ESTs, and control sequences. Biotinylated UTP complementary RNA (cRNA) probes were prepared, fragmented and hybridized to the microarrays for 16-18 h with constant rotation. The microarray slides were washed under stringent conditions, stained with Streptavidin-Alexa-647 (Invitrogen), and scanned using an Axon GenePix 4000B scanner. For data analyses, the local background was subtracted, and the spot intensities were log 2 -transformed. The spot intensities were then normalized by subtracting the 70th percentile of spot intensity of the probes against human constitutive exons and adding back a scaling factor (grand mean of 70th percentiles). After removing data for low quality spots, control sequences, and non-human probes, 41,213 human probe intensities remained. The human probes intensities were Wltered to identify all probes with intensity above a normalized threshold [log 2(3* standard deviation of raw local background) + mean of log2-transformed negative controls], to arrive at 23,291 probes above threshold in both samples from at least one group. For statistical analysis, samples were binned in two groups (Imatinib treated and control). The log2-transformed and normalized spot intensities for the detectable probes were examined for diVerences between the treatment groups by one-way ANOVA using National Institute of Aging (NIA) Array Analysis software. This ANOVA was conducted using the Bayesian Error Model and 20 degrees of freedom. Gene ontology analysis was performed using GenMAPP software (Gladstone Institute, San Francisco, CA) for all detectable probes with current Entrez Gene IDs. SpeciWcally, the MAPPWnder module of GenMAPP was Wrst used to map all detectable probes, based on their gene targets, to GO and Local MAPP categories. Then, MAPPWnder compared the relative representation in each functional group of genes associated with probes meeting one of Wve diVerential expression criteria to the relative representation of genes associated with the full set of detectable probes. SigniWcance was determined by permutation of Z scores with correction for multiple comparisons as described in the GenMAPP software manual. To shed light on the Imatinib-speciWc signaling pathways, all diVerentially expressed genes linked to GO terms identiWed in the microarray were subjected to pathway analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.
Transduction of MA-11 cells with lentiviral reporter gene constructs MA-11 cells were transduced with VSV-pseudotyped lentiviral particles expressing inducible reporter constructs encoding the luciferase gene under the control of a basal promoter element, joined to tandem repeats of a speciWc transcriptional response element (cignal Wnder lenti cancer 10-pathway reporter array kit, from SABiosciences, Frederick, MD). For transduction of MA-11 cells, lentiviral supernatants were preloaded onto recombinant Wbronectin (Retronectin, Takara Shuzo, Japan)-coated plates and centrifuged at 950g for 30 min at 4°C. The operation was repeated a second time with fresh supernatant. The supernatant was then removed, and the plates washed with PBS before addition of MA-11 cells in their complete culture medium. After transduction, stable cell lines expressing the speciWc transcriptional response elements were isolated via selection with 2 g/ml puromycin. Pathway-speciWc MA-11 cells were seeded at a density of 2 £ 10 4 per well in 24-well plates and grown to 50-60% conXuence. Cells were then treated with Imatinib or with the solvent for 24 h or for 9 days. The preparation of cell extracts and measurement of luciferase activities were carried out using the Steady-Glo Luciferase Reporter Assay System according to recommendations by the manufacturer (Promega, Madison, WI). The assays for luciferase activity were done in a 20/20 luminometer (Turner Biosystems, Sunnyvale, CA). The ratio of luciferase activity between Imatinib-and mocktreated samples was then calculated.
Results
EVects of Imatinib on MA-11 xenografts
To investigate the activity of Imatinib on breast cancer xenografts, we implanted 30,000 MA-11 cells s.c. in athymic nude mice and treated the animals i.p. with 60 mg/kg Imatinib diluted in phosphate-buVered saline for nine consecutive days, starting the day after the implantation of the tumor cells. Imatinib did not have an anti-tumor eVect, rather increased the tumorigenic potential of MA-11 cells and in 30% of animals caused the formation of large tumor masses in the intraperitoneal cavity. Table 1 shows the take rates in control and Imatinib-treated animals (30.8 and 84.6%, respectively). The average time to reach 1 cm 3 was 83.5 days for control animals and 41.1 days for animals exposed to Imatinib. To investigate whether a similar eVect on the growth of MA-11 xenografts occurred with a diVerent anti-cancer agent, we employed the chemotherapeutic drug, paclitaxel, on an additional cohort of mice. Mice were exposed to nine doses of 10 mg/kg paclitaxel for 9 days. As shown in Table 1 , no diVerence in the take rate was observed, with only a minor increase in time required to Presence of an abdominal tumor mass (%) 0 (n = 13) 30* (n = 13) 0 (n = 6) reach 1 cm 3 (83.5 vs. 101 days). A representative experiment with two control and two Imatinib-treated mice is shown in Fig. 1a . An hematoxylin-eosin-stained section from an abdominal MA-11 mass, showing a very cellular tumor, is represented in Fig. 1b. Reversible changes in the CD44 + CD24 ¡/low phenotype of MA-11 cells by Imatinib Originally, breast CSC were described as CD44 + CD24
¡/low cells. We have previously reported [7] that in MA-11 cells the level of CD24 expression is neither a stable feature of CSC-enriched cells grown as mammospheres nor confers tumorigenic potential to the cells. We now found that upon treatment of MA-11 cells with Imatinib, CD24 expression on the plasma membrane was almost completely lost in 3 days (Fig. 2) . The average number of CD24 molecules on the surface of MA-11 cells, measured by Xow cytometry, employing phycoerythrin-conjugated anti-human CD24 monoclonal antibodies and the quantum simply cellular system, decreased from 214,000 to 7,000 molecules/cell. Instead, CD44 did not change signiWcantly with Imatinib treatment, with the average number of CD44 molecules/cell going from 4,100,000 to 4,000,000 after 72 h exposure to Imatinib. But 24 and 48 h after removal of Imatinib from the culture medium, the average number of CD24 molecules/cell increased very rapidly to 21,000 and 45,000, respectively (Fig. 2 ). Microarray analysis (data not shown) conWrmed that 4 days after removal of Imatinib from the culture medium, CD24 expression was similar to that of control mock-treated cells.
In vitro study of the Imatinib-surviving fraction of MA-11 cells
To investigate the mechanism of the eVects of Imatinib on MA-11 cells, we simulated the in vivo treatment by exposing MA-11 cells in vitro for 9 days to 25 M Imatinib. After 9 days, the great majority of cells died. After growth and expansion in culture of the surviving cells for four additional days in the absence of Imatinib, we compared Imatinib-treated cells and the parental cell line for biological properties, chemosensitivity and gene expression pattern. First, we noticed that the motility of the cells increased, as measured by a conventional wound healing assay [9] . After 24 h, MA-11 cells pre-treated with Imatinib polarized toward the wound, initiated protrusion, migrated, and closed the wound faster than mock-treated cells (Suppl. Fig. 1) .
We then investigated the pattern of chemosensitivity of Imatinib-surviving cells by an MTS/PMS microtiter plate assay. Cells were exposed to the investigational drugs for 72 h. The level of resistance to Imatinib was twofold, while no changes in sensitivity to the cytotoxic activity of etoposide, paclitaxel, doxorubicin, antimony potassium tartrate and chlorambucil were observed ( Table 2 and Suppl. Fig. 2 ).
To investigate whether speciWc genes and/or signaling pathways were involved in the increased tumorigenicity and invasiveness of Imatinib-surviving MA-11 cells, we analyzed Imatinib-induced changes in gene expression proWle. By HEEBO microarray analysis of the gene expression proWles of two independent cultures each for control and Imatinib-surviving MA-11 cells, we found 877 probes showing signiWcant diVerences with P < 0.05 and FDR (false discovery rate) <5% (Suppl. Table 1 ). Excluding the non-annotated genes and multiple probes, only 301 and 241 genes were found to be signiWcantly up-and down-regulated, respectively (Suppl. Table 2 ). In all cases where multiple probes were available for the 542 genes, the changes in expression were very similar. First, we searched for Imatinib target genes, whose over-expression could cause resistance to Imatinib. We found that c-kit and pdgfr-alpha were not expressed in MA-11 cells, abl and pdgfr-beta were equally expressed between parental and Imatinib-treated cells, while CACNA1G, a T-type calcium channel, recently identiWed as an additional target of Imatinib, unrelated to the inhibition of tyrosine kinases [10] , was threefold overexpressed in Imatinib-treated cells (Suppl. Table 3) .
Although no diVerence in the cytotoxic activity of several chemotherapeutic agents was observed, 35 transporters were found diVerentially regulated in Imatinib-surviving versus control cells, including ABCC3 (MRP3), ABCC6 (MRP6), and several SLC (solute carrier) genes. The overexpression of SLC22A3 and ABCC3 was conWrmed by RT-PCR (Table 3) .
To shed light on Imatinib-induced or repressed signaling pathways, all genes diVerentially expressed in the microarray were subjected to pathway analysis and assigned to pathway networks. In particular, eight genes of the Wnt pathway were up-regulated, and Wve and six genes of the MAPK pathway were respectively up-and down-regulated in Imatinib-surviving cells (Suppl. Tables 4, 5). We then looked for genes associated with tumorigenicity, invasiveness, and/or the breast cancer stem cell phenotype, and we found that Imatinib-treated cells overexpress many genes associated with malignancy of breast cancer cells, including the mitochondrial benzodiazepine receptor TSPO, neurotensin, MMP-9, the inhibitor of cell death, COP1, and the aldehyde dehydrogenase gene, ALDH3A1, associated with the breast cancer stem cell phenotype [11] (Suppl. Table 6 ). We then employed RT-PCR to conWrm the diVerential expression of ten representative over-expressed genes. A good correlation between microarray and RT-PCR data was observed for all ten genes (Table 3) .
To further investigate the eVects of Imatinib on the WNT/ -catenin and the MAPK pathways, we analyzed the transcriptional activation of promoters driven by Wnt and MAPK proteins, using luciferase as reporter. To this aim, we transduced MA-11 cells with TCF/LEF and SRE lentiviral reporters, as well as with lentiviral reporters for eight additional cancer-related pathways, namely Notch, p53, TGF , Chlorambucil 500 § 150 600 § 100 pRB-E2F, NFkB, Myc, Hypoxia, and JNK. After puromycin selection, we exposed each reporter cell line to a short treatment (24 h) or a long treatment (9 + 4 days recovery) with 25 M Imatinib and analyzed the activity of the diVerent pathways by a luciferase assay. Figure 3 shows that in Imatinib-surviving cells only the Wnt/ -catenin, the MAPK/ Erk1-2, and the Myc pathways were activated (Fig. 3a) , while after 24-h exposure to Imatinib no signiWcant changes could be observed for any of the ten pathways investigated (Fig. 3b) .
Discussion
Despite novel therapeutic strategies for advanced and metastatic breast cancer, many patients relapse after an initial response to conventional and/or experimental drug treatments. In most cases, local and distant recurrences are associated with a more aggressive phenotype and resistance to therapy. It has been suggested that a small subpopulation of "tumor-initiating cells" or "cancer stem cells" (CSC) are resistant to therapy and hence may reinitiate tumor growth after treatment [1] . Chemotherapy-induced selection of CSC has been reported in several studies [12, 13] . However, the CSC that have survived Wrst-line therapy should re-establish a recurrent cancer that is similar to the original cancer both in biological behavior and susceptibility to Wrst-line therapy.
We have found that treatment of MA-11 cells in vitro with Imatinib results in a surviving population of cells with increased motility, that over-express a set of genes While selection of a CSC population could explain our in vitro data, it is not suYcient to justify our data of increased tumorigenicity and malignancy in immunodeWcient mice. Also, microarray analysis showed that stem cell markers or cancer stem cell markers were either not expressed in MA-11 cells or not diVerentially expressed: in particular, ALDH1, Notch3, CD133, Rex-1, Oct-4, Nanog were not expressed, and Sox-2 was equally expressed in Imatinib-treated and control MA-11 cells. In vitro treatment with Imatinib resulted in decreased expression of CD24, a marker negatively associated with the breast CSC phenotype. This is in agreement with observations by other groups of a decrease in CD24 expression in patients treated with neoadjuvant chemotherapy [14] , and that the CD44 +/
CD24
¡/low phenotype can be induced by genetic events or epigenetic events, such as exposure to TGF-beta, a factor secreted by tumor-associated stroma [15] . However, the rapidity of changes in CD24 expression observed in the present study was consistent with changes in the expression level of the antigen, not with selection of a CD24 ¡/low subpopulation. This is in agreement with our previous Wndings that the CD44 + CD24 ¡/low phenotype of MA-11 cells is reversible and unrelated to tumorigenicity and metastatic potential [7] .
Our in vivo Wndings may be attributed to epigenetic changes induced by the drug treatment, i.e. Imatinib-surviving cells activate some cell machinery that results in expression of a set of pro-malignant genes and consequently become endowed with pro-malignant properties. Alternatively, the in vivo eVects of Imatinib on MA-11 xenografts could be mediated, at least in part, by an immunosuppressive eVect of the drug cannot be excluded. Imatinib can adversely aVect the immune system by blocking immune surveillance of the malignancy and permitting disease recurrence. In fact, Imatinib reportedly inhibits activation, diVerentiation, and proliferation of normal T lymphocytes [16] , antigen presentation by dendritic cells [17] , and TNF secretion [18] . Also, Cristofanilli et al. [4] recently reported Imatinib-mediated inhibition of interferon-gamma production by TCR-activated CD4+ T cells in patients with PDGFR-beta-expressing advanced breast cancer.
By microarray analysis, we found that resistance to Imatinib of the surviving MA-11 cell population could be attributed to increased expression of the CACNA1G gene, a T-type calcium inhibitor recently identiWed as an additional target of Imatinib, and/or over-expression of the MRP3 transporter [19, 20] . The observed changes in expression for 35 SLC genes, which typically mediate uptake of nutrients (glucose, amino acids, organic anions, and peptides), may be related to increased energy and nutrition needs of cells with increased malignancy.
Interestingly, several genes potentially associated with the malignant phenotype of Imatinib-surviving cells were found to be over-expressed. Among these, TSPO, a mitochondrial permeability transition-pore protein involved in the regulation of apoptosis and cell proliferation that potentiates proliferation, motility, and transmigration capabilities of cancer cells [21] ; COP1 inhibitor of cell death that binds caspase 1 and caspase 4, blocking apoptosis [22] ; MMP-9, involved in the breakdown of the extracellular matrix and in the metastatic process; and Neurotensin, a trophic and anti-apoptotic factor associated with breast cancer progression that interacts with the neurotensin receptor on the cell membrane and stimulates Rho GTPases [23, 24] . Interestingly, many RhoGTPases were also over-expressed in Imatinib-surviving cells, and a link between neurotensin and MMP-9 has recently been demonstrated in breast cancer cells [23] . We have also found several signal transduction pathways, potential targets for anti-breast cancer therapy, diVerentially expressed in the Imatinib-surviving population versus the parental cell line. Among these, the Wnt/ -Catenin and the MAPK pathway, both recently found by our group to be altered in CSC-enriched MA-11 mammospheres compared with parental MA-11 cells [7] . The association of signiWcant changes in the Wnt/ -Catenin and the MAPK pathway with increased malignancy of breast cancer cells is supported by recent studies showing that aberrant activation of Wnt signaling induces mammary tumors from stem/progenitor cells [25] , and that activation of the classical MAPK/ERK pathway, leading to c-ras activation, is associated with breast cancer stem cells and breast tumor epithelial-mesenchymal transition [26, 27] . Our data suggest caution in the clinical use of Imatinib in breast cancer patients; the comparison of Imatinib-surviving and parental breast cancer cells may help understand the role of diVerentially expressed genes in tumorigenicity and invasiveness and deWne the regulatory pathways involved in the increased malignancy of residual tumor cells that survive therapy, ultimately providing important therapeutic targets.
